Table 2.
Summary of the frequency of positive expression of antibodies to various ribosomal P protein components in cerebrospinal fluida
| Percentage positiveb | |||
| Control | Diffuse NP-SLE | Focal NP-SLE | |
| Anti-PC22 | 4.2% (1/24) | 23.1% (12/52) | 5.3% (1/19) |
| Anti-whole P | 0% (0/24) | 78.8% (41/52) | 31.6% (6/19) |
| Anti-PEX.C22 | 4.2% (1/24) | 65.4% (34/52) | 26.3% (5/19) |
| Anti-C22-depleted rP0 | 5.3% (1/19) | 44.7% (21/47) | 5.6% (1/18) |
aAntibodies to the C-terminal 22-amino acid sequence of ribosomal P protein (anti-PC22), to highly purified ribosomal P proteins (anti-whole P), to the epitopes other than the C-terminal 22-amino acid sequence (anti-PEX.C22), and to recombinant ribosomal P0 protein lacking the C-terminal 22-amino acid sequence (anti-C22-depleted rP0) in cerebrospinal fluid from patients with non-inflammatory neurological diseases (Control), with diffuse neuropsychiatric systemic lupus erythematosus (NP-SLE), or with focal NP-SLE were compared. bCutoff values were set as the mean + 3 standard deviations of the values in control group. Values in parenthesis mean (numbers of patients with positive results/total patient numbers) in each group.